Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of CYT997 in Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma per International Working Group (IWG) criteria~* Have received at least 1 but no more than 4 prior lines of therapy~* Have failed to respond to the most recently administered anti-myeloma therapy~* Have a life expectancy of at least 3 months~* Eastern Cooperative Oncology Group (ECOG) performance status \< 3~* At registration absolute neutrophil count \> 1x10\^9/L and platelet count \> 50 x 10\^9/L unsupported~* At registration bilirubin less than 1.5 x upper limit of normal and transaminases less than 2 x upper limit of normal and serum creatinine less than 0.19 mmol/L~* Written informed consent~* Must agree to adequate contraceptive measure if indicated~Exclusion Criteria:~* Patients with monoclonal gammopathy of undetermined significance~* Known or suspected hypersensitivity to CYT997~* Patient with uncontrolled intercurrent illness~* Active infections or other illnesses that precludes chemotherapy administration or patient compliance.~* Pregnant or lactating women.~* Patients who have received any other investigational agents in the last 3 weeks prior to the start of treatment.~* Patients with the following conditions will be excluded:~  * myocardial infarction or stroke within 6 months~ * unstable angina pectoris or acute ischemic changes on ECG~ * history of diabetic retinopathy~ * symptomatic peripheral arterial disease~ * major surgery in the last 30 days~* Patients with uncontrolled diarrhea despite optimal medication and those with any history of acute gastrointestinal bleeding~* Patients with a baseline prolongation of the QTc interval of Common Terminology Criteria (CTC) Grade 1 (QTc \> 0.45-0.47 sec) or greater~* Patients with impaired cardiac function or clinically significant cardiac diseases, including any one of the following:~  * left ventricular ejection fraction (LVEF) \< 45% as determined by multigated acquisition (MUGA) scan or echocardiogram;~ * complete left bundle branch block;~ * obligate use of a cardiac pacemaker;~ * congenital long QT syndrome;~ * history or presence of ventricular tachyarrhythmia;~ * presence of unstable atrial fibrillation (ventricular response \> 100 bpm). -Patients with stable atrial fibrillation are eligible, provided they do not meet any of the other cardiac exclusion criteria;~ * clinically significant resting bradycardia (\< 50 bpm);~ * right bundle branch block + left anterior hemiblock (bifascicular block);~ * angina pectoris ≤ 3 months prior to starting study drug;~ * acute myocardial infarction (MI) ≤ 3 months prior to starting study drug; or~ * other clinically significant heart disease (e.g., congestive heart failure (CHF), uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen).~* Patients currently receiving treatment with medications known to prolong the QTc interval and/or to induce Torsades de Pointes arrhythmia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): CYT997

Based on this trial design, predict the completion outcome and termination type (if applicable).